PBE
Invesco Biotechnology & Genome ETF
Set alert
- YTD
- +24.77%
- 1 year
- +39.99%
- Open
- 103.47
- Prev close
- 103.46
- Mkt cap
- 315.42M
- Vol
- 13.14K
- Avg vol
- 30.18K
- EPS
- 3.66
- P/E
- 27.98
- Div yield
- 0.00%
More statistics
- Low
- 102.29
- High
- 104.24
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 69.17
- 200-d avg
- 67.04
News
1 week ago zacks.com
Why Healthcare ETFs Are Hovering Around One-Year Highs
Healthcare ETFs are hovering near 52-week highs as earnings prospects improve, clinical breakthroughs advance and GLP-1 demand expands. Explore five ETFs riding the rally.
2 weeks ago zacks.com
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
The Invesco Biotechnology & Genome ETF (PBE) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
2 weeks ago zacks.com
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the…
2 weeks ago fool.com
Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE?
One offers broad diversification at 0.08% cost, while the other targets concentrated biotech growth with higher volatility.
1 month ago benzinga.com
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
1 month ago fool.com
PBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors?
PBE offers a higher dividend yield and has delivered stronger one-year total returns. RSPH offers a more affordable expense ratio and a significantly lower historical drawdown.
1 month ago fool.com
iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy?
iShares U.S. Healthcare ETF offers a more diversified portfolio and lower expense ratio than Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total…
2 months ago fool.com
Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset?
IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.
2 months ago zacks.com
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund launched on 06/23/2005.
2 months ago fool.com
VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style?
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.
2 months ago zacks.com
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the…
3 months ago fool.com
XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?
State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to 0.58% for Invesco Biotechnology & Genome ETF Invesco Biotechnology & Genome ETF holds a…
3 months ago fool.com
VHT vs. PBE: Which Health Care ETF Is the Better Buy?
The Vanguard Health Care ETF (VHT) offers broader health care exposure and has a a lower expense ratio than the Invesco Biotechnology & Genome ETF (PBE). PBE has delivered a stronger 1-year return,…
3 months ago 247wallst.com
ETF Showdown: XBI vs PBE, Which Biotech Fund Wins?
At first glance, SPDR S&P Biotech ETF (NYSEARCA:XBI) and Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) look like two flavors of the same bet on drug discovery.
4 months ago etftrends.com
Biotech ETFs Gain Momentum via AI Drug Discovery & Surging M&A
The biotechnology sector has broken out of its multiyear bear market. As macroeconomic headwinds moderate and regulatory environments stabilize, biotech ETFs are surging.
4 months ago zacks.com
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Making its debut on 06/23/2005, smart beta exchange traded fund Invesco Biotechnology & Genome ETF (PBE) provides investors broad exposure to the Health Care ETFs category of the market.
4 months ago zacks.com
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the Invesco Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund…
6 months ago zacks.com
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund launched on 06/23/2005.
6 months ago zacks.com
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
The Invesco Biotechnology & Genome ETF (PBE) was launched on June 23, 2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the…
8 months ago zacks.com
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
The Invesco Biotechnology & Genome ETF (PBE) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
8 months ago zacks.com
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
The Invesco Biotechnology & Genome ETF (PBE) was launched on June 23, 2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the…
-
3 years ago benzinga.com
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval…
-
3 years ago benzinga.com
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.
-
3 years ago benzinga.com
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this…
-
3 years ago benzinga.com
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating…
-
3 years ago benzinga.com
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
-
3 years ago benzinga.com
US Judge Weighs Nationwide Ban On Abortion Pills
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is…
-
3 years ago benzinga.com
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
-
5 years ago benzinga.com
5 Top ETFs With Exposure To Biogen
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA.
-
5 years ago benzinga.com
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a
-
6 years ago benzinga.com
3 Health Care ETFs Where Components Are Enduring Downgrades
After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.
-
10 years ago benzinga.com
Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy
Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy
-
12 years ago benzinga.com
Biotech And Natural Gas ETFs On A Roll
Biotech And Natural Gas ETFs On A Roll
-
13 years ago benzinga.com
Biotech Breakout Highlights Flawed ETF Thinking
Biotech Breakout Highlights Flawed ETF Thinking
-
13 years ago benzinga.com
Interesting Similarities Among 2013's Top-Performing ETFs
Interesting Similarities Among 2013's Top-Performing ETFs
-
13 years ago benzinga.com
Under The Hood: An Unheralded Biotech ETF
Under The Hood: An Unheralded Biotech ETF
-
13 years ago benzinga.com
4 Health Care ETFs Your Broker Forgot to Mention
4 Health Care ETFs Your Broker Forgot to Mention
-
14 years ago benzinga.com
3 Unheralded ETFs Up More Than 10% in the Past 90 Days (PBE, TAGS)
3 Unheralded ETFs Up More Than 10% in the Past 90 Days (PBE, TAGS)
-
14 years ago benzinga.com
Arena Approval Boosts Biotech ETFs (ARNA, IBB, XBI)
Arena Approval Boosts Biotech ETFs (ARNA, IBB, XBI)
-
14 years ago benzinga.com
The Definitive Biotech ETF Guide (IBB, XBI, FBT)
The Definitive Biotech ETF Guide (IBB, XBI, FBT)
-
14 years ago benzinga.com
Viva Vivus, But Not In ETFs (VVUS, IBB, PJP)
Viva Vivus, But Not In ETFs (VVUS, IBB, PJP)
-
15 years ago benzinga.com
Five Health Care ETFs Your Broker Forget To Mention
Five Health Care ETFs Your Broker Forget To Mention
-
16 years ago benzinga.com
Five Biotech ETFs, Which One Is Worth A Look?
Five Biotech ETFs, Which One Is Worth A Look?